<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Biogen 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=24542></link><description><![CDATA[Biogen 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 22:28:32 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2015/03/3554153577_20150324092419_5477749571.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Biogen Appoints Michael Ehlers Executive Vice President, Research and Development]]></title><link>https://www.newswire.co.kr/newsRead.php?no=824541</link><description><![CDATA[CAMBRIDGE, Mass.--(Business Wire/Korea Newswire)--Biogen (NASDAQ: BIIB) today announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development.  Dr. Ehlers will oversee Biogen’s global Research, Drug Discovery, Clinical Development, and Medical Affairs functions, defining the strategic direction for the company’s R&amp;D organization and leading it...]]></description><pubDate>Thu, 28 Apr 2016 14:00:00 +0900</pubDate></item><item><title><![CDATA[Biogen Idec Becomes Biogen]]></title><link>https://www.newswire.co.kr/newsRead.php?no=786687</link><description><![CDATA[CAMBRIDGE, Mass.--(Business Wire/Korea Newswire)--Effective today, Biogen Idec is known simply as Biogen  (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need - while honoring Biogen’s scientific heritage and legacy as a pioneer in the biotechnology industry. For more in...]]></description><pubDate>Tue, 24 Mar 2015 09:30:00 +0900</pubDate></item></channel></rss>